Through this collaboration, Cereno Scientific and PHA Europe & Global will work together to integrate patient perspectives more systematically into the design and execution of clinical development programs. By incorporating patient insights into study protocols, materials, and communication, the collaboration is expected to contribute to more relevant, efficient, and patient-friendly clinical trials. The initiative also supports broader efforts to raise awareness of pulmonary hypertension, its challenges, and the unmet medical need, ultimately helping to reach and engage more patients globally.

“Patients are at the heart of everything we do at Cereno Scientific. Their experiences and insights are invaluable in shaping how we develop new treatments,” said Sten R. Sörensen, CEO of Cereno Scientific. “Through our clinical steering committee and ongoing dialogue with the patient community, we have already seen how patient input can enhance clinical trial execution. We are very pleased to partner with PHA Europe & Global to further strengthen this work, with the shared goal of improving the lives of people living with PAH and other pulmonary hypertension disease.”

By reinforcing a patient-centered approach, the collaboration aligns with Cereno Scientific’s broader strategy to develop disease-modifying therapies targeting the underlying mechanisms of rare diseases with high unmet needs. Engaging patients throughout the development process not only enhances the quality and relevance of clinical programs but also supports more effective communication and education efforts across stakeholders.

“We are delighted to collaborate with Cereno Scientific, a company that clearly recognizes the importance of placing patients at the center of drug development,” said Gerald Fischer, Managing Director of PHA Europe & Global. “By working together, we can ensure that the patient voice is heard and reflected in clinical research, while also increasing awareness and understanding of pulmonary hypertension and the daily challenges faced by patients and their families.”

PHA Europe & Global is a leading patient organization dedicated to improving the lives of people affected by pulmonary hypertension. The organization works to raise awareness, support patients and caregivers, and advocate for better access to diagnosis, care, and innovative treatments across Europe and globally.